Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.6622
+0.0200 (3.11%)
At close: Aug 24, 2026, 4:00 PM EDT
0.6678
+0.0056 (0.85%)
After-hours: Aug 24, 2026, 7:47 PM EDT
Humacyte Revenue
Humacyte had revenue of $406.00K in the quarter ending June 30, 2026, with 34.88% growth. This brings the company's revenue in the last twelve months to $2.12M, up 159.29% year-over-year. In the year 2025, Humacyte had annual revenue of $2.04M.
Revenue (ttm)
$2.12M
Revenue Growth
+159.29%
P/S Ratio
86.56
Revenue / Employee
$11,527
Employees
184
Market Cap
183.96M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Codexis | 77.68M |
| MediWound | 11.86M |
| Caribou Biosciences | 10.04M |
| Armata Pharmaceuticals | 5.54M |
| Korro Bio | 2.38M |
| Molecular Partners AG | 856.30K |
HUMA News
- 12 hours ago - Humacyte confirms plans for ATEV supplemental biologic license application - TheFly
- 12 hours ago - Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions - GlobeNewsWire
- 2 days ago - Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA - PRNewsWire
- 5 days ago - Humacyte publishes V007 results in The Lancet Digital Health - TheFly
- 5 days ago - Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - GlobeNewsWire
- 6 days ago - Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement” - GlobeNewsWire
- 7 days ago - Humacyte reports Q2 EPS (16c), consensus (10c) - TheFly
- 7 days ago - Humacyte price target lowered to $1 from $2 at Benchmark - TheFly